ACON
Aclarion, Inc.
Medical - Healthcare Information Services
Market Cap$3M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ACON vs XTNT
Revenue, margins, valuation, and 5-year total return — side by side.
XTNT
Xtant Medical Holdings, Inc.
Medical - Devices
Market Cap$81M
5Y Perf.-11.1%
ACON vs XTNT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ACON | XTNT |
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Devices |
| Market Cap | $3M | $81M |
| Revenue (TTM) | $75.73B | $133M |
| Net Income (TTM) | $-7.23T | $2M |
| Gross Margin | 9.0% | 62.0% |
| Operating Margin | -93.1% | 4.8% |
| Total Debt | $0.00 | $35M |
| Cash & Equiv. | $12.02T | $6M |
ACON vs XTNT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ACON
XTNT
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Aclarion, Inc. (ACON) | 100 | 0.0 | -100.0% |
| Xtant Medical Holdi… (XTNT) | 100 | 88.9 | -11.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACON vs XTNT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XTNT leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Aclarion, Inc. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
ACON
Aclarion, Inc.
The Growth Play
ACON is the clearest fit if your priority is growth exposure.
- Rev growth 1000K%, EPS growth 99.8%, 3Y rev CAGR 106.8%
- 1000K% revenue growth vs XTNT's 28.4%
- 100.0% yield; 1-year raise streak; the other pay no meaningful dividend
Best for: growth exposure
XTNT
Xtant Medical Holdings, Inc.
The Income Pick
XTNT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.69
- -97.6% 10Y total return vs ACON's -100.0%
- Lower volatility, beta 0.69, Low D/E 81.8%, current ratio 2.35x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ACON | 1000K% revenue growth vs XTNT's 28.4% |
| Quality / Margins | XTNT | 1.3% margin vs ACON's -95.5% |
| Stability / Safety | XTNT | Beta 0.69 vs ACON's 0.98 |
| Dividends | ACON | 100.0% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | XTNT | +13.5% vs ACON's -55.7% |
| Efficiency (ROA) | XTNT | 1.8% ROA vs ACON's -211.6%, ROIC -12.8% vs -12.9% |
ACON vs XTNT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
ACON vs XTNT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTNTLAGGINGACON
ACONAclarion, Inc.
1leads
XTNTXtant Medical Holding…
4leads
6 Total Categories
CATEGORYLEADERvs ACONMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
XTNT5/6
Valuation MetricsMultiples, price ratios, and targets
ACON2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTNT4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
XTNT6/6
Risk & VolatilityBeta, volatility, and downside exposure
XTNT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
XTNT leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACON is the larger business by revenue, generating $75.7B annually — 569.0x XTNT's $133M. XTNT is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to ACON's -95.5%. On growth, ACON holds the edge at +999999.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ACONAclarion, Inc. | XTNTXtant Medical Hol… |
|---|---|---|
| RevenueTrailing 12 months | $75.7B | $133M |
| EBITDAEarnings before interest/tax | -$7.05T | $11M |
| Net IncomeAfter-tax profit | -$7.23T | $2M |
| Free Cash FlowCash after capex | -$7.16T | $5M |
| Gross MarginGross profit ÷ Revenue | +9.0% | +62.0% |
| Operating MarginEBIT ÷ Revenue | -93.1% | +4.8% |
| Net MarginNet income ÷ Revenue | -95.5% | +1.3% |
| FCF MarginFCF ÷ Revenue | -94.6% | +3.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +999999.0% | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +99.9% | +123.7% |
XTNT leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
ACON leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ACONAclarion, Inc. | XTNTXtant Medical Hol… |
|---|---|---|
| Market CapShares × price | $3M | $81M |
| Enterprise ValueMkt cap + debt − cash | -$12.02T | $110M |
| Trailing P/EPrice ÷ TTM EPS | -0.24x | -4.81x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.00x | 0.69x |
| Price / BookPrice ÷ Book value/share | 0.00x | 1.80x |
| Price / FCFMarket cap ÷ FCF | — | — |
ACON leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
XTNT leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
XTNT delivers a 3.8% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-2 for ACON. On the Piotroski fundamental quality scale (0–9), ACON scores 4/9 vs XTNT's 2/9, reflecting mixed financial health.
| Metric | ACONAclarion, Inc. | XTNTXtant Medical Hol… |
|---|---|---|
| ROE (TTM)Return on equity | -2.3% | +3.8% |
| ROA (TTM)Return on assets | -2.1% | +1.8% |
| ROICReturn on invested capital | -12.9% | -12.8% |
| ROCEReturn on capital employed | -109.9% | -17.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | — | 0.82x |
| Net DebtTotal debt minus cash | -$12.02T | $29M |
| Cash & Equiv.Liquid assets | $12.02T | $6M |
| Total DebtShort + long-term debt | $0 | $35M |
| Interest CoverageEBIT ÷ Interest expense | — | 1.55x |
XTNT leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
XTNT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTNT five years ago would be worth $3,395 today (with dividends reinvested), compared to $0 for ACON. Over the past 12 months, XTNT leads with a +13.5% total return vs ACON's -55.7%. The 3-year compound annual growth rate (CAGR) favors XTNT at -3.9% vs ACON's -96.9% — a key indicator of consistent wealth creation.
| Metric | ACONAclarion, Inc. | XTNTXtant Medical Hol… |
|---|---|---|
| YTD ReturnYear-to-date | -34.1% | -23.1% |
| 1-Year ReturnPast 12 months | -55.7% | +13.5% |
| 3-Year ReturnCumulative with dividends | -100.0% | -11.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -66.1% |
| 10-Year ReturnCumulative with dividends | -100.0% | -97.6% |
| CAGR (3Y)Annualised 3-year return | -96.9% | -3.9% |
XTNT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
XTNT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XTNT is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than ACON's 0.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTNT currently trades 60.7% from its 52-week high vs ACON's 27.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ACONAclarion, Inc. | XTNTXtant Medical Hol… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 0.69x |
| 52-Week HighHighest price in past year | $12.03 | $0.95 |
| 52-Week LowLowest price in past year | $2.34 | $0.44 |
| % of 52W HighCurrent price vs 52-week peak | +27.3% | +60.7% |
| RSI (14)Momentum oscillator 0–100 | 45.4 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 103K | 143K |
XTNT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
ACON is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | ACONAclarion, Inc. | XTNTXtant Medical Hol… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $10196.68 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +43.3% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTNT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ACON leads in 1 (Valuation Metrics).
Best OverallXtant Medical Holdings, Inc. (XTNT)Leads 4 of 6 categories
Loading custom metrics...
ACON vs XTNT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ACON or XTNT a better buy right now?
For growth investors, Aclarion, Inc.
(ACON) is the stronger pick with 999999% revenue growth year-over-year, versus 28. 4% for Xtant Medical Holdings, Inc. (XTNT). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ACON or XTNT?
Over the past 5 years, Xtant Medical Holdings, Inc.
(XTNT) delivered a total return of -66. 1%, compared to -100. 0% for Aclarion, Inc. (ACON). Over 10 years, the gap is even starker: XTNT returned -97. 6% versus ACON's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ACON or XTNT?
By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.
(XTNT) is the lower-risk stock at 0. 69β versus Aclarion, Inc. 's 0. 98β — meaning ACON is approximately 43% more volatile than XTNT relative to the S&P 500.
04Which is growing faster — ACON or XTNT?
By revenue growth (latest reported year), Aclarion, Inc.
(ACON) is pulling ahead at 999999% versus 28. 4% for Xtant Medical Holdings, Inc. (XTNT). Over a 3-year CAGR, ACON leads at 106. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ACON or XTNT?
Xtant Medical Holdings, Inc.
(XTNT) is the more profitable company, earning -14. 0% net margin versus -95. 5% for Aclarion, Inc. — meaning it keeps -14. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XTNT leads at -10. 3% versus -93. 1% for ACON. At the gross margin level — before operating expenses — XTNT leads at 58. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ACON or XTNT?
In this comparison, ACON (100.
0% yield) pays a dividend. XTNT does not pay a meaningful dividend and should not be held primarily for income.
07Is ACON or XTNT better for a retirement portfolio?
For long-horizon retirement investors, Aclarion, Inc.
(ACON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), 100. 0% yield). Both have compounded well over 10 years (ACON: -100. 0%, XTNT: -97. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ACON and XTNT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
ACON pays a dividend while XTNT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ACON: 99999900.0% · XTNT: 19.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.